STAT+: Pharmalittle: J&J seeks emergency use for its coronavirus vaccine; Merck says parasite drug does not work on Covid-19
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is likely to be modest. We plan to celebrate another turning of the calendar with Mrs. Pharmalot, catch up on our reading, and schedule a few needed naps. And what about you? This is a fine time to enjoy the great outdoors, assuming you can keep your distance from other humans. Those of you on this side of the pond could prepare your taxes, since the treasury could use the money. Or you could reach out to someone feeling isolated. Well, whatever you do, have a grand time. But be safe — wear a mask. Enjoy, and see you soon. …
Johnson & Johnson (JNJ) has applied to the Food and Drug Administration for an emergency use authorization for its one-dose Covid-19 vaccine, setting in motion a process that is all but sure to see a third such vaccine authorized, STAT explains. If given the green light by the agency, the J&J vaccine will likely start being used in late February or early March, though initial supplies are expected to be extremely limited. The single dose makes it easier to deliver, as does the fact that the vaccine can be shipped and stored at refrigerator temperature.
Continue to STAT+ to read the full story…
